Recent Updates
Recently added Catalysts
STAA Negative Sentiment

STAAR Surgical Reports Third Quarter 2026 Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: STAAR Surgical reported a 12% decline in net sales for Q3 2026 compared to the previous year. However, excluding a significant drop, sales increased by 21%. The company continues to lead in the phakic IOL market with its EVO ICL product line. An earnings call is scheduled for further discussion.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company remains a leader in phakic IOLs.
  • Earnings call scheduled for investor engagement.

CONCERNS & RISKS

  • Net sales decreased by 12% year-over-year.
  • Sales growth was affected by a 33-percentage point drop.

Full Press Release Details

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended October 2, 2026. The Company will host an earnings call and webcast today at 5:30 PM Eastern Time. Third Quarter and Year-to-Date 2026 Highlights Include: Net sales down 12% Y/Y; up 21% excluding a 33-percentage point ($25.9

Frequently Asked Questions

What were STAAR Surgical's Q3 2026 net sales?

Net sales decreased by 12% year-over-year for Q3 2026.

How much did sales increase excluding certain factors?

Sales increased by 21% when excluding a 33-percentage point drop.

What product line does STAAR Surgical lead in?

STAAR Surgical is a leader in phakic IOLs with the EVO ICL product line.

When is the earnings call scheduled?

The earnings call is scheduled for today at 5:30 PM Eastern Time.

ShareAdd on Google
Tags: STAA STAAR Surgical Q3 2026 phakic IOLs EVO ICL
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$181M liquidity · $0M/mo burn
Low dilution risk